538 related articles for article (PubMed ID: 23873171)
1. Reduced prevalence of oral human papillomavirus (HPV) 4 years after bivalent HPV vaccination in a randomized clinical trial in Costa Rica.
Herrero R; Quint W; Hildesheim A; Gonzalez P; Struijk L; Katki HA; Porras C; Schiffman M; Rodriguez AC; Solomon D; Jimenez S; Schiller JT; Lowy DR; van Doorn LJ; Wacholder S; Kreimer AR;
PLoS One; 2013; 8(7):e68329. PubMed ID: 23873171
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of a bivalent HPV 16/18 vaccine against anal HPV 16/18 infection among young women: a nested analysis within the Costa Rica Vaccine Trial.
Kreimer AR; González P; Katki HA; Porras C; Schiffman M; Rodriguez AC; Solomon D; Jiménez S; Schiller JT; Lowy DR; van Doorn LJ; Struijk L; Quint W; Chen S; Wacholder S; Hildesheim A; Herrero R;
Lancet Oncol; 2011 Sep; 12(9):862-70. PubMed ID: 21865087
[TBL] [Abstract][Full Text] [Related]
3. Precancerous cervical lesions caused by non-vaccine-preventable HPV types after vaccination with the bivalent AS04-adjuvanted HPV vaccine: an analysis of the long-term follow-up study from the randomised Costa Rica HPV Vaccine Trial.
Shing JZ; Hu S; Herrero R; Hildesheim A; Porras C; Sampson JN; Schussler J; Schiller JT; Lowy DR; Sierra MS; Carvajal L; Kreimer AR;
Lancet Oncol; 2022 Jul; 23(7):940-949. PubMed ID: 35709811
[TBL] [Abstract][Full Text] [Related]
4. Reduced prevalence of vulvar HPV16/18 infection among women who received the HPV16/18 bivalent vaccine: a nested analysis within the Costa Rica Vaccine Trial.
Lang Kuhs KA; Gonzalez P; Rodriguez AC; van Doorn LJ; Schiffman M; Struijk L; Chen S; Quint W; Lowy DR; Porras C; DelVecchio C; Jimenez S; Safaeian M; Schiller JT; Wacholder S; Herrero R; Hildesheim A; Kreimer AR;
J Infect Dis; 2014 Dec; 210(12):1890-9. PubMed ID: 24958910
[TBL] [Abstract][Full Text] [Related]
5. Rationale and design of a double-blind randomized non-inferiority clinical trial to evaluate one or two doses of vaccine against human papillomavirus including an epidemiologic survey to estimate vaccine efficacy: The Costa Rica ESCUDDO trial.
Porras C; Sampson JN; Herrero R; Gail MH; Cortés B; Hildesheim A; Cyr J; Romero B; Schiller JT; Montero C; Pinto LA; Schussler J; Coronado K; Sierra MS; Kim JJ; Torres CM; Carvajal L; Wagner S; Campos NG; Ocampo R; Kemp TJ; Zuniga M; Lowy DR; Avila C; Chanock S; Castrillo A; Estrada Y; Barrientos G; Monge C; Oconitrillo MY; Kreimer AR
Vaccine; 2022 Jan; 40(1):76-88. PubMed ID: 34857420
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of the AS04-Adjuvanted HPV16/18 Vaccine: Pooled Analysis of the Costa Rica Vaccine and PATRICIA Randomized Controlled Trials.
Tota JE; Struyf F; Sampson JN; Gonzalez P; Ryser M; Herrero R; Schussler J; Karkada N; Rodriguez AC; Folschweiller N; Porras C; Schiffman M; Schiller JT; Quint W; Kreimer AR; Wheeler CM; Hildesheim A;
J Natl Cancer Inst; 2020 Aug; 112(8):818-828. PubMed ID: 31697384
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of the HPV-16/18 vaccine: final according to protocol results from the blinded phase of the randomized Costa Rica HPV-16/18 vaccine trial.
Hildesheim A; Wacholder S; Catteau G; Struyf F; Dubin G; Herrero R;
Vaccine; 2014 Sep; 32(39):5087-97. PubMed ID: 25018097
[TBL] [Abstract][Full Text] [Related]
8. Durability of Cross-Protection by Different Schedules of the Bivalent HPV Vaccine: The CVT Trial.
Tsang SH; Sampson JN; Schussler J; Porras C; Wagner S; Boland J; Cortes B; Lowy DR; Schiller JT; Schiffman M; Kemp TJ; Rodriguez AC; Quint W; Gail MH; Pinto LA; Gonzalez P; Hildesheim A; Kreimer AR; Herrero R;
J Natl Cancer Inst; 2020 Oct; 112(10):1030-1037. PubMed ID: 32091596
[TBL] [Abstract][Full Text] [Related]
9. Multisite HPV16/18 Vaccine Efficacy Against Cervical, Anal, and Oral HPV Infection.
Beachler DC; Kreimer AR; Schiffman M; Herrero R; Wacholder S; Rodriguez AC; Lowy DR; Porras C; Schiller JT; Quint W; Jimenez S; Safaeian M; Struijk L; Schussler J; Hildesheim A; Gonzalez P;
J Natl Cancer Inst; 2016 Jan; 108(1):. PubMed ID: 26467666
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of Durability of a Single Dose of the Bivalent HPV Vaccine: The CVT Trial.
Kreimer AR; Sampson JN; Porras C; Schiller JT; Kemp T; Herrero R; Wagner S; Boland J; Schussler J; Lowy DR; Chanock S; Roberson D; Sierra MS; Tsang SH; Schiffman M; Rodriguez AC; Cortes B; Gail MH; Hildesheim A; Gonzalez P; Pinto LA;
J Natl Cancer Inst; 2020 Oct; 112(10):1038-1046. PubMed ID: 32091594
[TBL] [Abstract][Full Text] [Related]
11. Sustainability of neutralising antibodies induced by bivalent or quadrivalent HPV vaccines and correlation with efficacy: a combined follow-up analysis of data from two randomised, double-blind, multicentre, phase 3 trials.
Mariz FC; Gray P; Bender N; Eriksson T; Kann H; Apter D; Paavonen J; Pajunen E; Prager KM; Sehr P; Surcel HM; Waterboer T; Müller M; Pawlita M; Lehtinen M
Lancet Infect Dis; 2021 Oct; 21(10):1458-1468. PubMed ID: 34081923
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial.
Paavonen J; Jenkins D; Bosch FX; Naud P; Salmerón J; Wheeler CM; Chow SN; Apter DL; Kitchener HC; Castellsague X; de Carvalho NS; Skinner SR; Harper DM; Hedrick JA; Jaisamrarn U; Limson GA; Dionne M; Quint W; Spiessens B; Peeters P; Struyf F; Wieting SL; Lehtinen MO; Dubin G;
Lancet; 2007 Jun; 369(9580):2161-2170. PubMed ID: 17602732
[TBL] [Abstract][Full Text] [Related]
13. Estimating human papillomavirus vaccine efficacy from a single-arm trial: proof-of-principle in the Costa Rica Vaccine Trial.
Befano B; Campos NG; Egemen D; Herrero R; Schiffman M; Porras C; Lowy DR; Rodriguez AC; Schiller JT; Ocampo R; Hildesheim A; Sampson JN; Das S; Kreimer AR; Cheung LC;
J Natl Cancer Inst; 2023 Jul; 115(7):788-795. PubMed ID: 37040086
[TBL] [Abstract][Full Text] [Related]
14. Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine.
Kreimer AR; Rodriguez AC; Hildesheim A; Herrero R; Porras C; Schiffman M; González P; Solomon D; Jiménez S; Schiller JT; Lowy DR; Quint W; Sherman ME; Schussler J; Wacholder S;
J Natl Cancer Inst; 2011 Oct; 103(19):1444-51. PubMed ID: 21908768
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA Trials.
Kreimer AR; Struyf F; Del Rosario-Raymundo MR; Hildesheim A; Skinner SR; Wacholder S; Garland SM; Herrero R; David MP; Wheeler CM; ; González P; Jiménez S; Lowy DR; Pinto LA; Porras C; Rodriguez AC; Safaeian M; Schiffman M; Schiller JT; Schussler J; Sherman ME; ; Bosch FX; Castellsague X; Chatterjee A; Chow SN; Descamps D; Diaz-Mitoma F; Dubin G; Germar MJ; Harper DM; Lewis DJ; Limson G; Naud P; Peters K; Poppe WA; Ramjattan B; Romanowski B; Salmeron J; Schwarz TF; Teixeira JC; Tjalma WA; ;
Lancet Oncol; 2015 Jul; 16(7):775-86. PubMed ID: 26071347
[TBL] [Abstract][Full Text] [Related]
16. Cross-protective vaccine efficacy of the bivalent HPV vaccine against HPV31 is associated with humoral immune responses: results from the Costa Rica Vaccine Trial.
Safaeian M; Kemp TJ; Pan DY; Porras C; Rodriguez AC; Schiffman M; Cortes B; Katki H; Wacholder S; Schiller JT; Gonzalez P; Penrose K; Lowy DR; Quint W; van Doorn LJ; Herrero R; Hildesheim A; Pinto LA
Hum Vaccin Immunother; 2013 Jul; 9(7):1399-406. PubMed ID: 23571174
[TBL] [Abstract][Full Text] [Related]
17. Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial.
Hildesheim A; Herrero R; Wacholder S; Rodriguez AC; Solomon D; Bratti MC; Schiller JT; Gonzalez P; Dubin G; Porras C; Jimenez SE; Lowy DR;
JAMA; 2007 Aug; 298(7):743-53. PubMed ID: 17699008
[TBL] [Abstract][Full Text] [Related]
18. Prevention of persistent human papillomavirus infection by an HPV16/18 vaccine: a community-based randomized clinical trial in Guanacaste, Costa Rica.
Herrero R; Wacholder S; Rodríguez AC; Solomon D; González P; Kreimer AR; Porras C; Schussler J; Jiménez S; Sherman ME; Quint W; Schiller JT; Lowy DR; Schiffman M; Hildesheim A;
Cancer Discov; 2011 Oct; 1(5):408-19. PubMed ID: 22586631
[TBL] [Abstract][Full Text] [Related]
19. Human papillomavirus prevalence and vaccine effectiveness in young women in Germany, 2017/2018: results from a nationwide study.
Loenenbach A; Schönfeld V; Takla A; Wiese-Posselt M; Marquis A; Thies S; Sand M; Kaufmann AM; Wichmann O; Harder T
Front Public Health; 2023; 11():1204101. PubMed ID: 37719724
[TBL] [Abstract][Full Text] [Related]
20. Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP).
Markowitz LE; Dunne EF; Saraiya M; Lawson HW; Chesson H; Unger ER; ;
MMWR Recomm Rep; 2007 Mar; 56(RR-2):1-24. PubMed ID: 17380109
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
